A Rare Case of Multiple Primary Malignancy Diagnosed with Pancreatic Adenocarcinoma After Diffuse Large B Cell Lymphoma
PDF
Cite
Share
Request
Case report
P: 481-484
2019

A Rare Case of Multiple Primary Malignancy Diagnosed with Pancreatic Adenocarcinoma After Diffuse Large B Cell Lymphoma

Acta Haematol Oncol Turc 2019;52(3):481-484
1. Department of Hematology, Baskent University Konya Application and Research Center, Konya, Turkey
2. Department of Anesthesiology, Konya Training and Research Hospital, Konya, Turkey
3. Department of Medical Pathology, Baskent University Konya Application and Research Center, Konya, Turkey
4. Department of Hematology, Faculty of Medicine, Selcuk University, Konya, Turkey
5.
No information available.
No information available
Received Date: 2019-05-09T16:35:20
Accepted Date: 2019-12-27T14:32:33
PDF
Cite
Share
Request

Abstract

The presence of at least two non-related malignancies in one patient is defined as Multiple Primer Maliginity. Diffuse large B-cell lymphoma (DLBCL) is the most common histopathological subtype of NHLs. Although many secondary malignancies have been reported with DLBCL, the association of DBBHL with pancreatic cancer is a very rare clinical entity. We report a rare case of multiple primary malignancies diagnosed as pancreatic cancer after remission of DBBHL. A 68-year-old man was diagnosed with DLBCL in another hospital and was in remission after eight cycles of chemotherapy. Approximately five months after the end of chemotherapy, weight loss, abdominal pain, loss of appetite, general state disorders appeared. The patient was admitted to our clinic with a mass in the pancreas and a metastatic lesion in the liver. Immunohistochemical findings of liver lesion were evaluated as adenocarcinoma metastasis. The patient was diagnosed with pancreatic cancer with clinical, pathological and laboratory findings. We think that differential diagnosis of newly developed secondary malignancies should be made when additional findings appear during the treatment and follow-up of primary malignancies.